The homegrown startup AarogyaAI is a SaaS (software-as-a-service) platform that offers the drug susceptibility status.
Leveraging AI (artificial learning) and ML (machine learning), the DNA sequence of a patient can be uploaded and the platform will analyse the sample to generate a report. It helps doctors to prescribe a more potent set of antibiotics to the patient.
Grow With Google
Last week, Google India unveiled the second cohort of its startup accelerator program for women founders. AarogyaAI is one of the 20 selected women-led startups.
AarogyaAI was founded by Avlokita Tiwari and Praapti Jayaswal in 2019. Its AI-powered genomics platform claims to transform healthcare by swiftly identifying and predicting antimicrobial resistance.
Commenting on the development, Co-founder and CTO, Tiwari said, "Google has mentors, cloud experts and product wizards that will help refine our product and enable us to do amazing work together."
The healthtech startup, run by the women duo, is set to enter its next phase of growth with support from Google. Furthermore, Tiwari said, "We are inching closer to being revenue-positive.”
In January 2022, the company secured USD 700k in seed funding round from Info Edge, Avaana Capital and Redstart Labs. The existing investors Entrepreneur First and First In Ventures also participated, according to media reports.
When asked about future plans for funding, she shared, ”We are currently in the midst of raising funds.”
The founders aspire to bring precision diagnosis to lower-tier cities worldwide. Tiwari emphasised, "Advancements in cloud computing and AI should be leveraged to make equitable healthcare access possible globally." This startup is poised for significant growth and impact in the healthcare sector.
Antibiotic resistance poses a grave global threat, leaving millions vulnerable to ineffective treatments. AarogyaAI is stepping up to confront this crisis with its groundbreaking solution.
Currently concluding a clinical trial at a major Indian hospital, AarogyaAI is eyeing to expand its presence to the European market.
Disclaimer: The views expressed in the article above are those of the authors' and do not necessarily represent or reflect the views of this publishing house